logo
Plus   Neg
Share
Email

Cambrex Corp. To Acquire Halo Pharma For $425 Mln - Quick Facts

Cambrex Corp. (CBM) announced a definitive agreement to acquire Halo Pharma (Halo), a dosage form Contract Development and Manufacturing Organization, majority owned by funds managed by the private investment firm SK Capital Partners, for approximately $425 million.

Halo operates two state-of-the-art, GMP compliant facilities located in Whippany, NJ, USA and Montreal, Québec, Canada. Halo is currently engaged in more than 100 product development projects for over 70 customers, and is expected to generate over $100 million in annual revenue in 2018. Halo's 450-person workforce will join Cambrex's 1,200 employees across the U.S. and Europe.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Aeronautics and Space Administration or NASA extended its contract with Boeing to build the rocket core stages for its Space Launch System or SLS beyond the first two Artemis missions, and through the next decade. Boeing is the current lead contractor for the core stages of the rockets for the first two missions. The new contract includes the production of ten SLS core stages. The U.S. Food and Drug Administration approved an all-time record total of 1,171 generic drugs in fiscal 2019, breaking its previous record of 971 approvals in fiscal 2018. This year's approvals include 935 full approvals and 236 tentative approvals. A generic drug is a pharmaceutical drug that contains the same chemical substance and performs the same functions as a branded drug. Air Canada has extended its grounding of Boeing's 737 MAX-8 aircraft and removed it from its flying schedule until February 14, 2020. The airline had earlier said its fleet of 24 grounded jetliners will not join its schedules until January 8, 2020. The Canadian flag carrier said the extension is a result of the ongoing regulatory uncertainty about the timing of the aircraft returning to service.
RELATED NEWS
Follow RTT
>